Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ovid Therapeutics Inc (OVID)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Ovid Therapeutics Announces Two Oral Presentations at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV)

-- New preclinical data provide further evidence of TAK-935/OV935's novel mechanism of action, as a potential treatment for rare developmental and epileptic encephaolopathies (dEE)

OVID : 7.67 (-5.89%)
Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress

-- Additional clinical trials planned in 2018 with OV101 for the treatment of adolescents and young adults with Fragile X syndrome and with TAK-935/OV935 for younger patient populations with dEE and additional...

OVID : 7.67 (-5.89%)
Ovid Therapeutics to Present at Deutsche Bank's 43rd Annual Health Care Conference on May 9, 2018

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced that management...

OVID : 7.67 (-5.89%)
DB : 12.25 (-4.89%)
Wired News - Axsome Therapeutics Initiated Phase-2 Clinical Trial of AXS-05 in Smoking Cessation

Stock Monitor: Ovid Therapeutics Post Earnings Reporting

OVID : 7.67 (-5.89%)
AXSM : 3.25 (-2.99%)
Wired News - Clementia Commenced Phase-2 MO-Ped Trial for Palovarotene in Pediatric Patients with Multiple Osteochondromas

Stock Monitor: Ovid Therapeutics Post Earnings Reporting

OVID : 7.67 (-5.89%)
CMTA : 15.04 (+0.60%)
Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress

-- Enrollment Completed in Phase 2 STARS Clinical Trial in Adults and Adolescents with Angelman Syndrome; Topline Data Expected Third Quarter 2018 --

OVID : 7.67 (-5.89%)
Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X Syndrome

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food...

OVID : 7.67 (-5.89%)
Ovid Therapeutics Announces Multiple Poster Presentations of OV101 and TAK-935/OV935 at the American Academy of Neurology 70th Annual Meeting

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it will present...

OVID : 7.67 (-5.89%)
Ovid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Yaron Werber, MD, chief business...

OVID : 7.67 (-5.89%)
Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation by U.S. FDA for Treatment of Lennox-Gastaut Syndrome

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the United States...

OVID : 7.67 (-5.89%)
TKPYY : 20.2900 (-1.81%)
Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food...

OVID : 7.67 (-5.89%)
TKPYY : 20.2900 (-1.81%)
Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting

- Phase 1 Clinical Trials of TAK-935/OV935 Demonstrated a Strong Safety Profile and Well Characterized Pharmacokinetic Profile, Supporting Further Clinical Advancement -

OVID : 7.67 (-5.89%)
Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include Adolescents

-- Results from the Phase 1 Clinical Trial of Adolescents with Angelman and Fragile X Syndromes Demonstrated OV101 was Well Tolerated with a Pharmacokinetic Profile Similar to Adults --

OVID : 7.67 (-5.89%)
Ovid Therapeutics to Participate in Two Upcoming Investor Conferences

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that it will participate in two upcoming...

OVID : 7.67 (-5.89%)
Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced financial results for the third quarter...

OVID : 7.67 (-5.89%)
Ovid Therapeutics to Participate at the Stifel 2017 Healthcare Conference

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Jeremy Levin, DPhil, MB BChir, chairman...

OVID : 7.67 (-5.89%)
Ovid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced new positive preclinical data on OV101...

OVID : 7.67 (-5.89%)
Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X Syndrome

Ovid Therapeutics, Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food...

OVID : 7.67 (-5.89%)
Ovid Therapeutics to Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced that it will provide a poster presentation...

OVID : 7.67 (-5.89%)
Ovid Therapeutics Appoints Ana C. Ward as Senior Vice President and General Counsel

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced the appointment of Ana C. Ward as senior...

OVID : 7.67 (-5.89%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU +1.14 , ABMD -1.06 , AAXN +2.28 , NSP +0.90 , ERI +1.00
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures were weak into the close on Thursday, down 3 to 4 1/4 cents lower in the front months. Traders were taking money off the table ahead of the extended weekend. The USDA reported a private cancelation of 132,000 of grain sorghum to unknown ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar